Janssen HJA, et al. - The clinicians evaluated the safety and efficacy of vesatolimod (GS-9620) after once-weekly treatment in chronic hepatitis B (CHB) infected patients suppressed on oral antiviral treatment. Among patients with chronic hepatitis B virus (HBV) infection, vesatolimod was safe and well-tolerated, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic IFNα expression induction or related symptoms. However, they observed no significant hepatitis B surface antigen (HBsAg) declines with vesatolimod treatment.